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Type I interferon (IFN) is a common therapy for autoim-
mune and inflammatory disorders, yet the mecha-
nisms of action are largely unknown. Here we showed
that type I IFN inhibited interleukin-1 (IL-1) production
through twodistinctmechanisms.Type I IFNsignaling,
via the STAT1 transcription factor, repressed the
activity of the NLRP1 and NLRP3 inflammasomes,
thereby suppressing caspase-1-dependent IL-1b
maturation. In addition, type I IFN induced IL-10 in a
STAT1-dependent manner; autocrine IL-10 then
signaled via STAT3 to reduce the abundance of
pro-IL-1a and pro-IL-1b. In vivo, poly(I:C)-induced
type I IFN diminished IL-1b production in response to
alum and Candida albicans, thus increasing suscepti-
bility to this fungal pathogen. Importantly, monocytes
frommultiplesclerosispatientsundergoingIFN-b treat-
ment produced substantially less IL-1b than mono-
cytes derived from healthy donors. Our findings may
thus explain the effectiveness of type I IFN in the treat-
ment of inflammatory diseases but also the observed
‘‘weakening’’ of the immunesystemafter viral infection.
INTRODUCTION
In response to cytosolic viral invasion, activation of intracellular
RIG-I-like receptors triggers interferon-b (IFN-b) production
(Meylan et al., 2006). Specialized immune cells can also produce
type I IFN (both IFN-a and IFN-b) in response to extracellular
stimuli of viral or bacterial origin by toll-like receptor (TLR)
engagement. For example, conventional dendritic cells (cDCs)
and macrophages produce IFN-a and IFN-b in response to
TLR3 and TLR4 stimulation. In addition, plasmacytoid dendritic
cells (pDCs), a specialized type of IFN-producing antigen-pre-
senting cell (APC), can also produce type I IFN in response to
TLR-7 and TLR-9 ligands (Meylan et al., 2006; Stetson and
Medzhitov, 2006).Type I IFNs bind to a common receptor, the type I IFN receptor
(IFNAR), composed of two subunits (namely IFNAR1 and
IFNAR2), which are associated with the Janus kinases (JAKs)
tyrosine kinase 2 (TYK2) and JAK1. Activation of TYK2 and
JAK1 causes phosporylation of signal transducers and activa-
tors of transcription-1 (STAT1) and STAT2, leading to the forma-
tion of a trimeric complex composed of phosphorylated STAT1
(pSTAT1), pSTAT2, and IFN regulatory factor 9 (IRF9). This
complex translocates to the nucleus where it binds to IFN-stim-
ulated response elements (ISREs), motifs present in promoters
and enhancers of interferon-stimulated genes (ISGs), to regulate
transcription. Moreover, pSTAT1 homodimers, STAT3, and
STAT5 can play a role downstream of IFNAR (Platanias, 2005).
Particular attention has been paid to the anti-inflammatory
effects exerted by type I IFN, demonstrated by two lines of
evidence (Billiau, 2006; Theofilopoulos et al., 2005). First,
patients recovering from a primary viral infection are often
more susceptible to secondary infection. In such circumstances,
an immunosuppressive role of a- and b-IFNs was suggested by
several reports (Decker et al., 2005; Jensen et al., 1992; Shahan-
gian et al., 2009). Second, a number of studies show the effec-
tiveness of this family of cytokines in reducing inflammation in
different experimental settings and, most importantly, type I
IFN is successfully used in the clinic, not only for the treatment
of diseases of viral origin but also for the management of
diseases such as multiple sclerosis (MS) (Barkhof et al., 2007;
Billiau, 2006; Comi et al., 2001; Giovannoni and Miller, 1999).
For patients suffering from MS in the relapsing-remitting phase
(RR-MS), IFN-bmarkedly attenuates the course and the severity
of the disease, contributing to the maintenance of the blood-
brain barrier integrity and reducing the occurrence of relapses.
More recently, IFN treatment has also been successfully used
for patients suffering from familiar Mediterranean fever (FMF)
and from Behcet’s syndrome, two inflammatory disorders linked
to IL-1 overproduction (Ko¨tter et al., 2004; Tweezer-Zaks et al.,
2008).
IL-1b and IL-1a are two potent proinflammatory cytokines,
which share a common IL-1 receptor (IL-1R). IL-1b is synthe-
sized as an inactive precursor, pro-IL-1b, which requires
cleavage by caspase-1 in order to attain its active form (indicated
as p17, because of its molecular weight of 17 kDa), whereasImmunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc. 213
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1987). Caspase-1 activation is accomplished within a protein
complex known as ‘‘inflammasome,’’ which comprises, beside
caspase-1 and its substrate pro-IL-1b, a sensor protein (Marti-
non et al., 2002). To date, four different sensors able to induce
inflammasome platform assembly have been identified,
NLRP1b, NLRP3, IPAF (NLRC4), and AIM2, which trigger the
formation of the inflammasome in response to distinct stimuli
(Martinon et al., 2009; Schroder et al., 2009).
Though IL-1b contributes to the control of several pathogenic
infections, such as Salmonella typhimurium and Candida
albicans (Bellocchio et al., 2004; Gross et al., 2009; Lara-Tejero
et al., 2006), an excessive production of this cytokine has been
associated with several autoinflammatory and/or autoimmune
conditions such as FMF or cryopyrin-associated periodic
syndromes (McDermott and Tschopp, 2007).
Despite the growing use of type I IFN in the clinic, the mecha-
nisms underlying its protective effects in autoimmune and
inflammatory disorders are still poorly understood. Some reports
propose a role for IFN-b in altering integrin and matrix metallo-
proteinase expression or activity, thereby reducing leukocyte
infiltration to the site of inflammation (Billiau, 2006). IFN-b was
also shown to alter the production of several cytokines involved
in T cell polarization or in inflammation, including IL-1b (Billiau,
2006; Coclet-Ninin et al., 1997; Huang et al., 1995; Masters
et al., 2010;Zanget al., 2004).However, themechanismsexplain-
ing this observation and their relevance to the clinic have never
been thoroughly assessed. Specifically, the effects of type I IFN
on inflammasome-dependent cytokinematuration havenot been
investigated. We therefore examined the possible role of type I
IFN in controlling inflammasome activity and IL-1 production,
which might account for both the efficacy of IFNs in therapeutic
settings and the immunosuppressive effects of this cytokine after
viral infection. We indeed found that type I IFN strongly sup-
pressed IL-1 production. This was due to STAT1-dependent
inhibition of NLRP3 and NLRP1 inflammasome activity. In addi-
tion, in bone marrow-derived macrophages (BMDMs), type I
IFN enhanced the production of IL-10, which in turn decreased
the levels of pro-IL-1a and pro-IL-1b. In vivo, pro-IL-1b induced
by aluminum salts and Candida albicans was suppressed by
type I IFN, renderingmicehighly susceptible toCandida infection.
Moreover, monocytes derived from IFN-b-treated MS patients
showed decreased IL-1b production in response to inflamma-
some stimulation, recapitulating the suppressive effects of type
I IFN observed in vitro and in vivo in the murine model.
RESULTS
IFN-b Suppresses Both Pro-IL-1b Availability
and IL-1b Maturation
To assess the anti-inflammatory effects of type I IFN on IL-1
production, we incubated BMDMs for 12 hr with IFN-b. Cells
were then primed with lipopolysaccharide (LPS) for 4 hr in order
to induce pro-IL-1b synthesis and stimulated with alum to acti-
vate IL-1b maturation via the NLRP3 inflammasome. We found
that IFN-b blocked the secretion of IL-1b by suppressing the
activation of both caspase-1 and the intracellular pro-IL-1b
pool (Figure 1A). Inflammasome inhibition and pro-IL-1b reduc-
tion appeared within a few hours of IFN-b stimulation (Figure S1A214 Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc.available online) and could not be ascribed to cell death (Fig-
ure S1B). Furthermore, by using Ifnar1-deficient BMDMs, we
ensured that the effects of IFN-b on inflammasome activity and
pro-IL-1b were specific to its receptor (Figure 1B). We next
asked whether type I IFN could exert similar effects also on
bone marrow-derived dendritic cells (BMDCs) and found that
caspase-1 activation was inhibited by both IFN-b and IFN-a,
whereas the suppressive effect on pro-IL-1b was not observed
in this cell type (Figure 1C). Thus, depending on the cell type,
type I IFN can regulate the production of the proinflammatory
cytokine IL-1b at two levels: by inhibiting inflammasome function
and by reducing the pool of intracellular pro-IL-1b.
In order to rule out the possibility that IFN-b-dependent inflam-
masome suppression was due to interference with LPS priming,
NLRP3 inflammasome activity was assayed in cells without prior
priming and in cells that were primed with LPS for 4 hr. As shown
in Figure 1D, inflammasome-mediated caspase-1 activation was
inhibited by IFN-a and -b independently of priming, whereas
IFN-g failed to decrease inflammasome function and intracellular
levels of pro-IL-1b under these conditions. Nevertheless, when
overnight LPS priming was employed, suppression by type I
IFN was most prominent and IFN-g also displayed inhibitory
activity (Figure S1C). In an attempt to determine themechanisms
mediating the observed cross talk between LPS and IFNs, we
assessed IFN receptor-proximal signaling and the amounts of
signal transducing factors (Figure S1D). No significant differ-
ences were observed, suggesting that the diverging responses
to type I and II IFNs observed upon different priming regimes
are due to downstream integration events of LPS and IFN-b
signaling pathways.
Not surprisingly, the secretion of the caspase-1-dependent
cytokines IL-1b, IL-18, and IL-1a was strongly diminished
when BMDMwere pretreated with IFN-b (Figure 1E). In contrast,
the amounts of secreted TNF were not significantly altered (Fig-
ure S1E), whereas the expression of CD40 and CD86 were even
enhanced by IFN-b (Figure S1F). Together, these results show
that IFN-b decreases IL-1 and IL-18 production, though it does
not affect BMDM activation in a general way.
IFN-b Inhibits NLRP1- and NLRP3-Triggered
Inflammasome Activity
To determine whether the suppression exerted by IFN-b specif-
ically affected alum-dependent NLRP3 inflammasome activity,
we tested other NLRP3 agonists and found that NLRP3 inflam-
masome activity after monosodium urate crystals (MSU),
asbestos, nigericin, ATP, and C. albicans was repressed by
IFN-b, similar to alum (Figure 2A).
In order to define whether the effect of IFN-b were confined to
NLRP3 or extended to other inflammasome types, we assessed
the effects of IFN-b pretreatment on the NLRP1b, IPAF, and
AIM2 inflammasomes by activating these inflammasomes with
B. anthracis lethal toxin (LeTx), S. typhimurium, or intracellular
delivery of poly(deoxyadenylic-thymidylic) acid (poly(dA:dT)),
respectively. Similar to the NLRP3, NLRP1b-dependent inflam-
masome activity was inhibited by IFN-b (Figure 2B), whereas
IPAF-inflammasome and ASC-dependent but NLRP3-indepen-
dent AIM2-inflammasome were unaffected by IFN-b pretreat-
ment (Figures 2C and 2D). As expected, in all cases mature
IL-1b amounts were diminished by IFN-b, reflecting the
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Figure 1. IFN-b Decreases Inflammasome
Activity and Pro-IL-1b
(A and B) BMDMs were incubated 12 hr with the
indicated doses of IFN-b. Thereafter, LPS was
added to prime BMDMs and, 4 hr later, alum
stimulation was performed. IL-1b and caspase-1
activation and release were assessed by immuno-
blot. (B) BMDMs of wild-type (WT) and of Ifnar1/
origin were used.
(C) As for (A), but with BMDCs instead of BMDMs
and IFN-b or IFN-a.
(D) BMDMs were incubated overnight with IFN-b,
IFN-a, or IFN-g. LPS was either not added, or
added the last 4 hr preceding alum stimulation.
(E) BMDMs were treated with IFN-b overnight for
12 (o/n) or for 5 hr (5h) and primed with LPS for
4 hr. Cells were then stimulated with alum and
cytokines measured by ELISA. Data represent
mean ± SD of three individual experimental points.
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Type I IFN Inhibits IL-1 Productiondecreased amounts of intracellular pro-IL-1b (Figure 2C and
data not shown). Thus, IFN-b specifically inhibits the activity of
NLRP1b and NLRP3 inflammasomes.
Type I IFN-Induced IL-10 Controls IL-1b
and IL-1a Precursor Levels
A potential role for STAT3 in the suppressive effects downstream
of IFNARwas suggested by the inflammatory phenotype of Stat3
myeloid-specific conditional deleted mice (LysMcre Stat3flox/)
(Takeda et al., 1999). Though type I IFN-dependent caspase-1
inhibition was unaltered by Stat3 deletion when compared to
control Stat3flox/ BMDMs (Figure 3A), the reduction of intracel-Immunity 34, 213–223,lular pro-IL-1b and pro-IL-1a was much
less prominent in Stat3-deficient cells
(Figure 3A). This suggested that type I
IFN induces an inhibitory factor, which is
likely to signal via STAT3, that diminishes
IL-1b and IL-1a precursor amounts.
Given that the evidence for STAT3
involvement in IFNAR signaling is not
compelling and that STAT3 is known to
be involved in signaling downstream of
IL-10 receptor (IL-10R), we tested the
contribution of the anti-inflammatory
cytokine IL-10 to the reduction of IL-1
precursor protein. We found that the
suppression of LPS-induced pro-IL-1b
and pro-IL-1a amounts induced by 5 hr
or overnight incubation with IFN-b was
strongly abolished in Il10/ BMDMs
(Figure 3B; Figure S2). In line with this,
exogenous IL-10 decreased the abun-
dance of IL-1b and IL-1a precursor
proteins in wild-type (WT) cells (Fig-
ure 3C), whereas this was not the case
in LysMcre Stat3flox/ BMDMs, suggest-
ing a crucial role for STAT3 in the
IL-10-mediated reduction of pro-IL-1b
and pro-IL-1a amounts. Ifnar1/ and
BMDMs lacking the IFN key transcription factor STAT1
(Stat1/) diminished IL-1 precursor amounts in response to
IL-10, but failed to do so upon type I IFN (Figure 3C), indicating
that IL-10 production is downstream of IFNAR-triggered
pathway. Taken together, these results suggest a model in
which type I IFN induces secretion of IL-10, which subsequently
downregulates pro-IL-1 expresssion through activation of
IL-10R and STAT3.
In support of such a mechanism, we found strong IL-10 secre-
tion by WT and conditional LysMcre Stat3flox/ BMDMs upon
type I IFN plus subsequent LPS exposure, which was not
apparent in Ifnar1/ and Stat1/ cells (Figure 3D).February 25, 2011 ª2011 Elsevier Inc. 215
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Figure 2. IFN-b Inhibits NLRP3 and NLRP1b
Inflammasomes
BMDMswere cultured overnight in the presence or
absence of IFN-b. LPS was added to prime the
BMDMs during the last 4 hr preceding inflamma-
some stimulation. Data are representative of at
least three individual experiments.
(A–C) Caspase-1 activation and IL-1b release in
supernatants after stimulation with alum, MSU,
asbestos (Asb), nigericin (Nig), ATP, and C. albi-
cans (C.a.) (A), after LeTx stimulation (B), or after
S. typhimurium (S. typhi.) infection (C).
(D) Caspase-1 release by BMDMs of WT, Asc/,
and Nlrp3/ origin after poly(dA:dT) transfection.
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Type I IFN Inhibits IL-1 ProductionType I IFN Inhibits NLRP3 Inflammasome Activation
in a STAT1-Dependent Manner
Next,we testedwhether inflammasome inhibitionby type I IFNwas
mediated via the IFNAR-STAT1 pathway. Indeed in Stat1/ cells,
type I IFN could no longer inhibit caspase-1 activation (Figure 4A).
STAT1 can be phosphorylated at residues tyrosine 701 or
serine 727. Tyrosine phosphorylation is required for nuclear
translocation of STAT1 and transcription factor function (Plata-
nias, 2005). We therefore tested whether type I IFN efficiently
suppressed the inflammasome in BMDMs in which STAT1 can
be exclusively phosphorylated at the tyrosine residue (in which
serine 727 is substituted with an alanine residue (Stat1S727A)).
Our results indicate that serine phosphorylation is dispensable
(Figure 4B), suggesting that tyrosine phosphorylation is sufficient
for inflammasome inhibition.
Next, we asked whether the inflammasome inhibitory factor
was secreted. We tried to rescue type I IFN-dependent inflam-
masome inhibition in Ifnar1/BMDMsby coculturing these cells
with caspase-1-deficient (Casp1/) BMDMs, which should nor-
mally respond to IFN. As shown in Figure 4C, Casp1/ cells
were unable to restore inflammasome inhibition in Ifnar1/ cells,
suggesting that the inhibitory factor is unlikely to be secreted.
Because the known inflammasome components NLRP3, ASC,
and caspase-1 also appeared not to be downregulated by type
I IFN (Figure 4D), we hypothesized that an intracellular negative
regulator of the inflammasome may be induced by STAT1.
Several proteins have been suggested to function as caspase-1
or inflammasome inhibitors, including the proteinase inhibitors216 Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc.serpin peptidase inhibitor, clade B,
member 9 (Serpinb9, also called SPI-6)
and Serpinb2 (also known as PAI-2),
caspase-12, pyrin (also called mediterra-
nean fever), and the Bcl family members
Bcl-2 and Bcl-XL (also known as BCL2-
like 1) (Guarda and So, 2010). We exam-
ined whether these candidates were up-
regulated by type I IFN (by using as
a control the IFN-inducible chemokine
CXCL10) or whether their deletion
affected inflammasome activity (Figures
S3A and S3B). However, none of these
proteins were significantly induced by
type I IFN or were essential for IFN-medi-
ated inhibition of the inflammasome.Taken together, our results indicate that STAT1 inhibits
NLRP3-mediated caspase-1 activation by an as yet undefined
mechanism.
Type I IFN Suppresses IL-1-Dependent Inflammatory
Cell Recruitment In Vivo
We next asked whether the effects of in vitro IFN treatment on
IL-1 production were similar in vivo. We pretreated mice intrave-
nously (i.v.) with polyinosinic-polycytidylic acid (poly(I:C)), a
synthetic RNA analog that strongly induces type I IFN produc-
tion, and subsequently injected them with alum intraperitoneally
(i.p.), thus inducing an IL-1-dependent peritonitis that is lost in
Il1r1/ mice, as illustrated in Figure S4A. Peritoneal exudate
cells (PECs) were collected and cytokine content in the lavages
was measured. We found that alum challenge upregulated
mature IL-1b secretion in the lavage fluid and that this was pre-
vented by poly(I:C) pretreatment (Figure 5A). We also observed
that pro-IL-1b amounts were reduced in PEC extracts from
mice pretreated with poly(I:C) (Figure 5B), whereas pro-IL-1a
was undetectable (data not shown). All of the aforementioned
effects were not observed in Ifnar1/ animals (Figures 5A and
5B), indicating that the effects elicited by poly(I:C) treatment
are dependent on type I IFN.
We consequently analyzed alum-induced recruitment of
inflammatory cells in control mice or in mice pretreated i.v. with
poly(I:C). The number of total PECs recruited upon alum chal-
lenge was strongly reduced in mice pretreated with poly(I:C)
(Figure 5C). In line with this observation, neutrophil and Ly6C+
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Figure 3. Type I IFN Regulates Pro-IL-1
Levels via IL-10 and STAT3
(A) BMDMs from control (Stat3flox/) or LysMcre
Stat3flox/ (cre Stat3flox/) mice were incubated
12 hr with IFN-b or IFN-a. Thereafter, LPS was
added to prime the BMDMs and, 4 hr later, alum
stimulation was performed. Caspase-1 activation
and IL-1b release are shown in supernatants, pro-
caspase-1, pro-IL-1b, or pro-IL-1a levels in cell
lysates.
(B) BMDMs from WT or Il10/ mice were incu-
bated 5 hr with IFN-b, followed by 4 hr LPS treat-
ment. Pro-IL-1b and pro-IL-1a levels were as-
sessed in cell lysates.
(C and D) BMDMs from WT, Ifnar1/, Stat1/,
LysMcre Stat3flox/, or control (Stat3flox/) mice
were incubated 5 hr with IFN-b, IFN-a (C and D),
or IL-10 (C), followed by 4 hr LPS treatment. Pro-
IL-1b and pro-IL-1a levels in cell lysates were
measured by immunoblot (C), IL-10 levels by
ELISA (D). Data represent mean ± SD of three indi-
vidual experimental points (D).
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Type I IFN Inhibits IL-1 Productionmonocyte recruitment was significantly blocked by poly(I:C)
pretreatment (Figures 5D and 5E). In order to exclude the proba-
bility that the observed reduction was due to a general defect
induced by poly(I:C) onmigratory cells, zymosan, which is known
to induce a peritonitis independently of IL-1, was used in parallel
(Figures 5C–5E; Dostert et al., 2009; Martinon et al., 2006). In this
case, PECs, neutrophils, and (to a lesser extent) Ly6C+ mono-
cytes were still recruited to the peritoneum despite the poly(I:C)
pretreatment, further demonstrating that poly(I:C) suppresses
alum-induced peritonitis by blocking the generation of IL-1.A B
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I IFN Is STAT1 Dependent
(A and B) C57BL/6 (WT), Stat1/ (A), and
Stat1S727A knockin (S727A) (B) BMDMswere incu-
bated 12 hr with IFN-b or IFN-a. Thereafter, LPS
was added to prime the BMDMs and, 4 hr later,
alum stimulation was performed. Caspase-1 acti-
vation and IL-1b release are shown in superna-
tants, procaspase-1, pro-IL-1b, and pro-IL-1a
levels in cell lysates.
(C) BMDMs from C57BL/6 (WT), Ifnar1/, or
Caspase1/ (Casp1/) were cultured alone or
cocultured as indicated. Cells were incubated
12 hr with IFN-b or IFN-a, followed by 4 hr LPS
and alum stimulation. Caspase-1 activation was
assessed by immunoblot in culture supernatants.
(D) BMDMs were stimulated for the indicated
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two. Expression of inflammasome components
was assessed by immunoblot in cell lysates.
Data are representative of two to four individual
experiments.
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Figure 5. Type I IFN Decreases the Inflammatory Response to Alum
C57BL/6 or Ifnar1/mice were injected with poly(I:C) (pIC) i.v. or left untreated as a control. 5 hr later, mice were challenged with alum, zymosan, or poly(I:C) (pIC
i.p.) i.p.
(A and B) 2 hr after alum injection, peritoneal cavities were lavaged. IL-1b content in the lavage fluid wasmeasured by ELISA (A), while PECs recovered were lysed
and analyzed for their expression of pro-IL-1b by immunoblot (B). Values are themean ± SEM of five to eight mice per group, pooled from two independent exper-
iments (A), while in (B) individual mice are represented in each lane.
(C–E) 12–14 hr after alum or zymosan injection, mice were sacrificed and peritoneal lavages performed. Absolute numbers of PECs, neutrophils, or Ly6C+mono-
cytes recruited to the peritoneum are depicted.
(F–H) 12–14 hr after alum injection, C57BL/6 or Ifnar1/ mice were sacrificed and peritoneal lavages performed. Absolute numbers of PECs, neutrophils, or
Ly6C+ monocytes recruited to the peritoneum are depicted.
(C–H) Data represent mean ± SEM of the pool of two independent experiments, and results for individual mice are illustrated.
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Type I IFN Inhibits IL-1 Productionpoly(I:C) in vitro (Figures S4B andS4C).We also saw no evidence
for poly(I:C)-dependent inflammasome activation in vivo (Fig-
ure 5D), because i.p. injection of poly(I:C) did not trigger neutro-
phil influx, a hallmark of IL-1 production (Chen et al., 2006).
Type I IFN Increases Susceptibility
to C. albicans Infection
Treatment of mice with poly(I:C) impairs their survival to
C. albicans infection (Jensen et al., 1992; Worthington and Ha-
senclever, 1972). Given the importance of IL-1 in the control of218 Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc.this infection (Figure S5A; Bellocchio et al., 2004), we wondered
whether under those circumstances, poly(I:C)-induced type I
IFNmight decrease IL-1, thus explaining increased susceptibility
to C. albicans. We compared survival after C. albicans challenge
of naive or poly(I:C)-pretreatedWTmice and Ifnar1/mice. Poly
(I:C)-primed WT mice showed dramatically increased suscepti-
bility to C. albicans infection as compared to unprimed mice
(Figure 6A), whereas poly(I:C)-primed Ifnar1/ mice survived
C. albicans challenge similar to unprimed animals (Figure 6B).
The premature death of WT poly(I:C)-treated animals was found
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Figure 6. Type I IFN Worsens Susceptibility
to C. albicans Infection
(A–D) WT, Ifnar1/, or Stat1/mice were treated
or not with poly(I:C) (pIC) i.v. and 5 hr later, mice
were infected i.v. with C. albicans (C.a.). On day
1, poly(I:C)-treated mice were injected a second
time with poly(I:C).
(A, B, D) Survival of the different cohorts of mice
was monitored for 7 days postinfection. Data are
representative of at least two independent experi-
ments (per condition, n = 9–10 for WT, n = 4–6 for
Ifnar1/ or Stat1/ mice).
(C) C. albicans load was assessed in the kidneys
of 2 day infected mice by counting C. albicans
cfu/kidney in the indicated groups. Cfu per kidney
are represented as mean ± SEM of the pool of two
experiments (9–10 mice per group).
(E) WT or Ifnar1/ mice were treated or not with
poly(I:C) i.v. and 5 hr later, mice were infected
i.p. with 106 or i.v. with 107 C. albicans fungal cells.
3 hr after i.p. injection and 5 hr after i.v. injection,
PECs or blood were harvested, respectively. Intra-
cellular content of pro-IL-1bwas then assessed by
immunoblot.
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Type I IFN Inhibits IL-1 Productionto be due to a defective control ofC. albicans, as indicated by the
fact that kidneys of these animals contained significantly more
colony forming units (CFU) than the kidneys of unprimed WT
mice and the kidneys of poly(I:C)-treated Ifnar1/ animals
(Figure 6C). We also tested the outcome of poly(I:C) priming on
C. albicans infection in Stat1/ mice (Figure 6D). As expected,
Stat1/mice resisted the detrimental effects of poly(I:C) priming
on candidiasis progression. Intriguingly, we noticed that poly
(I:C)-primed Stat1/ mice and, to a lesser extent, poly(I:C)-
primed Ifnar1/ animals showed a tendency to slightly better
survive C. albicans infection compared to their unprimed coun-
terparts (Figures 6B and 6D). We also assessed the role of
IFN-g in STAT1-mediated C. albicans susceptibility and found,
as predicted from our in vitro data, that type II IFN is not playing
a dominant role (Figure S5B).
We then verified whether poly(I:C)-induced type I IFN was
indeed reducing the IL-1 response to C. albicans in vivo. We
challenged poly(I:C)-primed or -unprimed WT and Ifnar1/
animals with C. albicans i.p. or i.v. and then analyzed the levels
of pro-IL-1b in PECs and blood, respectively. As shown in Fig-
ure 6E, poly(I:C)-induced type I IFN clearly decreased the ability
of the mice to produce pro-IL-1b upon C. albicans challenge.
IFN-b Suppresses IL-1b Production in Human
Primary Monocytes
To investigate whether type I IFN exerts the same anti-inflamma-
tory effects in human cells, primary monocytes were isolated
from blood of healthy donors (HDs) and cultured overnight withImmunity 34, 213–223,IFN-b, primed with LPS, and then stimu-
lated with alum. In line with findings from
mice, incubation with IFN-b effectively
diminished alum-induced IL-1b secretion
and caspase-1 cleavage (Figures 7A and
7B). As shown in Figure 7C, even at low
concentrations IFN-b significantly sup-pressed IL-1b production. Similar to what was observed in
mouse BMDMs, a striking decrease in pro-IL-1b accompanied
by IL-10 induction was noted (Figure 7B; Figure S6A). Thus,
type I IFN plays a crucial role in the negative regulation of both
caspase-1 activity and pro-IL-1b production in human primary
monocytes.
IFN-b is currently used in the management of several diseases
including MS. We therefore asked whether IFN-b treatment in
RR-MS patients similarly suppresses IL-1b production. First,
we confirmed that the recombinant IFN-b preparations adminis-
tered to the patients (IFN-b-1a, Rebif, produced in mammalian
cells, and IFN-b-1b Betaferon, produced in bacteria) had the
same in vitro effects on IL-1b production as the IFN-b used for
research purposes (Figure S6B). Finally, monocytes isolated
from blood of MS patients on IFN-b therapy were challenged
ex vivo with alum in the presence or the absence of LPS priming
or left untreated (Figure 7D). IL-1b production by monocytes
derived from both Rebif- and Betaferon-treated patients
released significantly less IL-1b than monocytes derived from
HDs. Taken together, these results suggest that a possible
mode of action for the success of IFN-b treatment for MS might
indeed rely on suppressing IL-1-mediated inflammation.
DISCUSSION
In addition to its antiviral effects, type I IFN is acknowledged
as an immunomodulatory cytokine, though the underlying
mechanisms are poorly understood. Our work suggests thatFebruary 25, 2011 ª2011 Elsevier Inc. 219
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Figure 7. IFN-b Suppresses IL-1b Production by Human Primary Monocytes
(A–C) Human primary monocytes were cultured overnight in the presence of 1000 U/ml (A, B) or the indicated doses of human IFN-b (C). LPS was added to prime
themonocytes for 3 hr, followed by stimulation with alum. IL-1b release wasmeasured by ELISA and data represent mean ± SD of 3 experimental replicates (A) or
mean ± SEM of 10 individual donors (C). Caspase-1 activation in the supernatants after stimulation with alum and pro-IL-1b levels in cell lysates are shown in (B).
(D) Monocytes from RR-MS patients treated with Rebif or Betaferon, and in parallel, from age- and gender-matched HDs were primed with 3 hr LPS exposure or
left unprimed. Then, cells were stimulated with alum. IL-1b release was measured by ELISA and data represent mean ± SEM of 9 Rebif-treated RR-MS patients,
9 Betaferon-treated RR-MS patients, and 15 untreated healthy donors.
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Type I IFN Inhibits IL-1 Productionthe anti-inflammatory effects exerted by type I IFNmay be due at
least partially to its ability to control IL-1 production. IL-1a, which
does not require processing by caspase-1, is reduced in BMDMs
upon incubation with type I IFN, whereas secretion of active
IL-1b is abolished by two distinct means: through the reduction
of pro-IL-1b protein and via suppression of NLRP1b and
NLRP3 inflammasome-dependent caspase-1 activation. Such
inflammasome inhibition by IFN also provides a mechanism for
the observed interferon-dependent suppression of IL-18 matu-
ration, as shown by the fact that IL-18 maturation also depends
on inflammasome activity.
The predominant mechanism leading to type I IFN-dependent
suppression of pro-IL-1b and pro-IL-1a is based on the STAT1-
mediated synergistic action of type I IFN and LPS to induce
IL-10. IL-10, in turn, regulates pro-IL-1b and pro-IL-1a amounts
in a STAT3-dependent manner. In agreement with a previous
report (Hu et al., 2006), the ability to induce IL-10 is specific to
type I IFN, thus nicely supporting our observation that IFN-g
does not significantly decrease the levels of pro-IL-1b and pro-
IL-1a. The mechanism by which IL-10 exerts its anti-inflamma-220 Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc.tory effects is still the object of intense research, but the reduction
of IL-1 precursor levels may represent one important pathway.
STAT1 is crucial for the inhibition of NLRP3 inflammasome
activity by type I IFNs. We found that phosphorylation at tyrosine
701 was sufficient for the suppression of NLRP3 inflammasome
activity, whereas the serine 727 modification was dispensable.
Tyrosine phosphorylation is required and sufficient for STAT1
nuclear translocation and DNA binding to target promotors,
whereas modification of serine 727 appears to enhance STAT1
transactivator function. This suggests that transcriptional induc-
tion of a target gene was required for the inflammasome-sup-
pressing activity of type I IFN. Our results also indicate that the
inhibitory pathway is likely to be cell intrinsic, but future studies
will be needed to further characterize this pathway.
IL-1b has been reported to play a role in controlling viral infec-
tions such as influenza. Moreover, viral RNA and poly(I:C) were
reported to induce release of IL-1b through activation of the
NLRP3 inflammasome (Allen et al., 2009; Kanneganti et al.,
2006). Interestingly, we observed an increase in intracellular
pro-IL-1b upon poly(I:C) exposure, in particular in vitro. However,
Immunity
Type I IFN Inhibits IL-1 Productionwe could detect neither activation of caspase-1 nor release of
mature IL-1b under these circumstances. In vivo, poly(I:C) trig-
gered strong induction of type I IFN that efficiently prevented
further pro-IL-1b induction by exogenous inflammasome
agonists. Hence, depending on the type of infection, the balance
between the induction of type I IFN and pro-IL-1b could indeed
dictate the final level of mature IL-1b.
The capacity of type I IFNs to suppress inflammasome activity
and IL-1 production is relevant to the phenomenon of superin-
fections. It is well established that although infections with
viruses such as influenza are very common, mortalities purely
attributable to the primary viral infection are relatively rare.
Many influenza-related deaths are caused by secondary bacte-
rial infections, which present a unique clinical challenge resulting
from the emergence of antibiotic resistance and increased
severity of infection. Influenza infections impair innate immune
function and several mechanisms for the increased susceptibility
to secondary bacterial infections have been proposed, some of
which are dependent on type I IFNs (Shahangian et al., 2009).
Our data suggest that the ability of type I IFN to suppress inflam-
masome activity and IL-1 secretion may contribute to the
increased risk of infection after viral exposure. In line with this,
we showed that poly(I:C)-induced type I IFN rendered WT mice
as susceptible to C. albicans infection as Il1r1/ mice (Belloc-
chio et al., 2004; Kullberg et al., 1990; Van’t Wout et al., 1988;
Vonk et al., 2006). To further corroborate our hypothesis, we
showed that poly(I:C)-induced type I IFN suppressed an effective
IL-1 response to C. albicans infection. In an analogous manner,
Medzhitov’s laboratory delineated a mechanism by which influ-
enza virus leads to suppression of the host immune response
and to increased susceptibility to secondary bacterial infection
through glucocorticoid induction (Jamieson et al., 2010). Inter-
estingly, IL-1b is inhibited by glucocorticoid hormones in vivo
and in vitro (Fantuzzi and Ghezzi, 1993).
The contributions of IL-1 and IL-18 to the development of
inflammatory and autoimmune manifestations are well
described (Chae et al., 2009; Furlan et al., 1999a, 1999b; Kant-
arci et al., 2002). These include MS, where interleukin-1b and
interleukin-1 receptor antagonist gene polymorphisms were
found to be associated with disease severity (Kantarci et al.,
2002). Although more experimental evidence is required, it is
tempting to speculate that the successful treatment of MS with
IFN is mediated, at least in part, by its ability to suppress the
IL-1-inflammasome axis. Such a notion is supported by our
observation that inflammasome activity is suppressed in mono-
cytes from patients under IFN therapy. Our data retrospectively
shed light on some aspects of the widespread use of IFN in the
treatment of autoimmune and/or inflammatory diseases and
suggest that inflammasome inhibitors may complement current
treatment regimes.
EXPERIMENTAL PROCEDURES
Mice
Mice were treated in accordance with the Swiss Federal Veterinary Office
guidelines.
In Vitro Stimulation Experiments
BMDMs and BMDCs were differentiated as previously described (Guarda
et al., 2009). 5 3 104 differentiated BMDMs or BMDCs were incubated for12 hr or the indicated times in the presence of 500 U/ml IFN-b, 500 U/ml
IFN-a11 (both from PBL Interferon Source), 20 ng/ml IFN-g (Calbiochem), or
20 ng/ml IL-10 (Peprotech) unless otherwise specified. According to what
was indicated, cells were primed with 10 ng/ml ultrapure LPS (Invivogen) either
for 12 hr (at the same time as IFN treatment), for the 4–6 hr preceding inflam-
masome stimulations, or left unprimed. Then, stimulations were carried out.
ATP (500 mM), nigericin (0.4 mM), and MSU crystals (300 mg/ml) were from
Sigma. Asbestos (300 mg/ml) was from SPI-CHEM and alum (300 mg/ml)
from Pierce Biochemicals (Imject-alum). ATP stimulations were performed
for 45 min, other stimulations for 150 min (unless otherwise indicated).
C. albicans was put on BMDMs at a multiplicity of infection of 1 for 150 min.
B. anthracis LeTx stimulation and S. typhimurium infection were carried out
as previously described (Guarda et al., 2009). For the stimulation of the
AIM-2 inflammasome, poly(dA:dT) (purchased from Amersham) was admixed
at the indicated concentrations to Lipofectamine 2000 (from Invitrogen)
according to manufacturer’s instructions and cells were stimulated for 6 hr.
Isolation of Human Primary Monocytes
We obtained buffy coats from the Lausanne Blood Transfusion Center. Addi-
tionally, healthy volunteers and RR-MS patients on Rebif or Betaferon treat-
ment (receiving their last IFN-b injection at the same day or up to 3 days prior
to blood collection) donated 40ml of blood after informed consent. Blood draw
for this study was accepted by our institution’s ethical commission and all
subjects gave their written consent according to review board guidelines.
Stimulation of Human Primary Monocytes
Monocytes from RR-MS patients or healthy donors were plated at
150,000 cells/well and left untreated or primed with 1 ng/ml LPS (Invivogen)
for 3 hr. Unprimed or primed monocytes were subsequently stimulated for
6 hr with 500 mg/ml alum (Pierce). For in vitro IFN-b treatment, CD14+ mono-
cytes were incubated with the indicated amounts of IFN-b (Peprotech) for
12 hr followed by 3 hr LPS priming and 6 hr alum stimulation. To test the
production of IL-10 upon IFN-b exposure, CD14+ monocytes were incubated
in the presence of IFN-b for 12 hr and then stimulated with LPS for 4 hr or left
unstimulated.
In Vivo Peritonitis and Candida albicans Infection Experiments
For peritonitis, mice were injected i.v., unless otherwise indicated, with 200 mg
poly(I:C) (Invivogen) followed by a second i.p. injection of alum 5 hr later. For
the analysis of PECs, 350 mg alum (Pierce) or 350 mg zymosan (Invivogen) as
control were injected. 12–14 hr after alum injection, mice were sacrificed
and peritoneal cavities were washed with 6 ml PBS. PECs were analyzed by
FACS. For the analysis of IL-1b in the peritoneal cavity, 5 hr after i.v. injection
of 200 mg poly(I:C), mice were injected i.p. with 700 mg alum. Lavages and
PECs were harvested 2 hr later, and peritoneal fluids were concentrated for
ELISA analysis with Amicon Ultra 10K from Millipore.
C. albicanswas cultured on Chromagar Candida plates (BD Bioscience). For
C. albicans infections, mice were injected i.v., with 200 mg poly(I:C), followed
by a second i.v. injection of 2.5 3 105 fungal cells 5 hr later. The day after,
mice treated with poly(I:C) were injected again i.v. with 100 mg poly(I:C). For
analysis of C. albicans load, mice were sacrificed 48 hr after infection, and
homogenized kidneys were plated on Chromagar Candida plates to determine
colony forming units. For survival assay, mice were monitored with a score-
sheet, in accordance with local guidelines for animal experimentation.
Statistical Analysis
Statistical differences were calculated with an unpaired Student’s t test, two-
tailed (GraphPad Prism version 5.0). Differences were considered significant
when p% 0.05 (*), very significant when p% 0.01 (**), and extremely significant
when p% 0.001 (***).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/
j.immuni.2011.02.006.Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc. 221
Immunity
Type I IFN Inhibits IL-1 ProductionACKNOWLEDGMENTS
We acknowledge patients and healthy volunteers for their contribution to this
study by donating blood. We thank M. Aguet, ISREC (Lausanne), H. Acha-Or-
bea, UNIL (Lausanne), A. Suhrbier, Queensland Institute of Medical Research
(Brisbane), and P. Ashton-Rickardt, Imperial College London (London) for
knockout mice; M.Winter (University of Duesseldorf), R. Castillo, and O. Gross
for technical help; and K. Schroder and C. Thomas for critical reading of the
manuscript. This work was in part supported by the Swiss National Science
Foundation and by the Institute for Arthritis Research. M.B. and P.R. are sup-
ported by the Swiss National Science foundation and P.R. also by the NCCR
Molecular Oncology.
Received: July 10, 2010
Revised: October 22, 2010
Accepted: December 2, 2010
Published online: February 24, 2011REFERENCES
Allen, I.C., Scull, M.A., Moore, C.B., Holl, E.K., McElvania-TeKippe, E.,
Taxman, D.J., Guthrie, E.H., Pickles, R.J., and Ting, J.P. (2009). The NLRP3 in-
flammasome mediates in vivo innate immunity to influenza A virus through
recognition of viral RNA. Immunity 30, 556–565.
Barkhof, F., Polman, C.H., Radue, E.W., Kappos, L., Freedman, M.S., Edan,
G., Hartung, H.P., Miller, D.H., Montalba´n, X., Poppe, P., et al. (2007).
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT
study: Integrated 2-year results. Arch. Neurol. 64, 1292–1298.
Bellocchio, S., Montagnoli, C., Bozza, S., Gaziano, R., Rossi, G., Mambula,
S.S., Vecchi, A., Mantovani, A., Levitz, S.M., and Romani, L. (2004). The contri-
bution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immu-
nity to fungal pathogens in vivo. J. Immunol. 172, 3059–3069.
Billiau, A. (2006). Anti-inflammatory properties of Type I interferons. Antiviral
Res. 71, 108–116.
Chae, J.J., Aksentijevich, I., and Kastner, D.L. (2009). Advances in the under-
standing of familial Mediterranean fever and possibilities for targeted therapy.
Br. J. Haematol. 146, 467–478.
Chen, C.J., Shi, Y., Hearn, A., Fitzgerald, K., Golenbock, D., Reed, G., Akira, S.,
and Rock, K.L. (2006). MyD88-dependent IL-1 receptor signaling is essential
for gouty inflammation stimulated by monosodium urate crystals. J. Clin.
Invest. 116, 2262–2271.
Coclet-Ninin, J., Dayer, J.M., and Burger, D. (1997). Interferon-beta not only
inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates inter-
leukin-1 receptor antagonist production in human peripheral blood mononu-
clear cells. Eur. Cytokine Netw. 8, 345–349.
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Ferna´ndez, O., Hartung,
H., Seeldrayers, P., Sørensen, P.S., Rovaris, M., et al; Early Treatment of
Multiple Sclerosis Study Group. (2001). Effect of early interferon treatment
on conversion to definite multiple sclerosis: A randomised study. Lancet
357, 1576–1582.
Decker, T., Mu¨ller, M., and Stockinger, S. (2005). The yin and yang of type I
interferon activity in bacterial infection. Nat. Rev. Immunol. 5, 675–687.
Dostert, C., Guarda, G., Romero, J.F., Menu, P., Gross, O., Tardivel, A., Suva,
M.L., Stehle, J.C., Kopf, M., Stamenkovic, I., et al. (2009). Malarial hemozoin is
a Nalp3 inflammasome activating danger signal. PLoS ONE 4, e6510.
Fantuzzi, G., and Ghezzi, P. (1993). Glucocorticoids as cytokine inhibitors:
Role in neuroendocrine control and therapy of inflammatory diseases.
Mediators Inflamm. 2, 263–270.
Furlan, R., Filippi, M., Bergami, A., Rocca, M.A., Martinelli, V., Poliani, P.L.,
Grimaldi, L.M., Desina, G., Comi, G., andMartino, G. (1999a). Peripheral levels
of caspase-1 mRNA correlate with disease activity in patients with multiple
sclerosis; a preliminary study. J. Neurol. Neurosurg. Psychiatry 67, 785–788.
Furlan, R., Martino, G., Galbiati, F., Poliani, P.L., Smiroldo, S., Bergami, A.,
Desina, G., Comi, G., Flavell, R., Su, M.S., and Adorini, L. (1999b). Caspase-1222 Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc.regulates the inflammatory process leading to autoimmune demyelination.
J. Immunol. 163, 2403–2409.
Giovannoni, G., and Miller, D.H. (1999). Multiple sclerosis and its treatment.
J. R. Coll. Physicians Lond. 33, 315–322.
Gross, O., Poeck, H., Bscheider, M., Dostert, C., Hannesschla¨ger, N., Endres,
S., Hartmann, G., Tardivel, A., Schweighoffer, E., Tybulewicz, V., et al. (2009).
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host
defence. Nature 459, 433–436.
Guarda, G., and So, A. (2010). Regulation of inflammasome activity.
Immunology 130, 329–336.
Guarda, G., Dostert, C., Staehli, F., Cabalzar, K., Castillo, R., Tardivel, A.,
Schneider, P., and Tschopp, J. (2009). T cells dampen innate immune
responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature
460, 269–273.
Hu, X., Paik, P.K., Chen, J., Yarilina, A., Kockeritz, L., Lu, T.T., Woodgett, J.R.,
and Ivashkiv, L.B. (2006). IFN-gamma suppresses IL-10 production and
synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins.
Immunity 24, 563–574.
Huang, Y., Blatt, L.M., and Taylor, M.W. (1995). Type 1 interferon as an antiin-
flammatory agent: Inhibition of lipopolysaccharide-induced interleukin-1 beta
and induction of interleukin-1 receptor antagonist. J. Interferon Cytokine Res.
15, 317–321.
Jamieson, A.M., Yu, S., Annicelli, C.H., and Medzhitov, R. (2010). Influenza
virus-induced glucocorticoids compromise innate host defense against
a secondary bacterial infection. Cell Host Microbe 7, 103–114.
Jensen, J., Vazquez-Torres, A., and Balish, E. (1992). Poly(I.C)-induced inter-
ferons enhance susceptibility of SCID mice to systemic candidiasis. Infect.
Immun. 60, 4549–4557.
Kanneganti, T.D., Body-Malapel, M., Amer, A., Park, J.H., Whitfield, J.,
Franchi, L., Taraporewala, Z.F., Miller, D., Patton, J.T., Inohara, N., and
Nu´n˜ez, G. (2006). Critical role for Cryopyrin/Nalp3 in activation of caspase-1
in response to viral infection and double-stranded RNA. J. Biol. Chem. 281,
36560–36568.
Kantarci, O.H., de Andrade, M., and Weinshenker, B.G. (2002). Identifying
disease modifying genes in multiple sclerosis. J. Neuroimmunol. 123,
144–159.
Ko¨tter, I., Gu¨naydin, I., Zierhut, M., and Stu¨biger, N. (2004). The use of inter-
feron alpha in Behc¸et disease: Review of the literature. Semin. Arthritis
Rheum. 33, 320–335.
Kullberg, B.J., van ’t Wout, J.W., and van Furth, R. (1990). Role of granulocytes
in increased host resistance to Candida albicans induced by recombinant
interleukin-1. Infect. Immun. 58, 3319–3324.
Lara-Tejero, M., Sutterwala, F.S., Ogura, Y., Grant, E.P., Bertin, J., Coyle, A.J.,
Flavell, R.A., and Gala´n, J.E. (2006). Role of the caspase-1 inflammasome in
Salmonella typhimurium pathogenesis. J. Exp. Med. 203, 1407–1412.
Martinon, F., Burns, K., and Tschopp, J. (2002). The inflammasome: a molec-
ular platform triggering activation of inflammatory caspases and processing of
proIL-beta. Mol. Cell 10, 417–426.
Martinon, F., Pe´trilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006).
Gout-associated uric acid crystals activate the NALP3 inflammasome.
Nature 440, 237–241.
Martinon, F., Mayor, A., and Tschopp, J. (2009). The inflammasomes:
Guardians of the body. Annu. Rev. Immunol. 27, 229–265.
Masters, S.L., Mielke, L.A., Cornish, A.L., Sutton, C.E., O’Donnell, J., Cengia,
L.H., Roberts, A.W., Wicks, I.P., Mills, K.H., and Croker, B.A. (2010).
Regulation of interleukin-1beta by interferon-gamma is species specific,
limited by suppressor of cytokine signalling 1 and influences interleukin-17
production. EMBO Rep. 11, 640–646.
McDermott, M.F., and Tschopp, J. (2007). From inflammasomes to fevers,
crystals and hypertension: How basic research explains inflammatory
diseases. Trends Mol. Med. 13, 381–388.
Meylan, E., Tschopp, J., and Karin, M. (2006). Intracellular pattern recognition
receptors in the host response. Nature 442, 39–44.
Immunity
Type I IFN Inhibits IL-1 ProductionMosley, B., Urdal, D.L., Prickett, K.S., Larsen, A., Cosman, D., Conlon, P.J.,
Gillis, S., and Dower, S.K. (1987). The interleukin-1 receptor binds the human
interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J. Biol.
Chem. 262, 2941–2944.
Platanias, L.C. (2005). Mechanisms of type-I- and type-II-interferon-mediated
signalling. Nat. Rev. Immunol. 5, 375–386.
Schroder, K., Muruve, D.A., and Tschopp, J. (2009). Innate immunity:
Cytoplasmic DNA sensing by the AIM2 inflammasome. Curr. Biol. 19,
R262–R265.
Shahangian, A., Chow, E.K., Tian, X., Kang, J.R., Ghaffari, A., Liu, S.Y.,
Belperio, J.A., Cheng, G., and Deng, J.C. (2009). Type I IFNs mediate
development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest.
119, 1910–1920.
Stetson, D.B., and Medzhitov, R. (2006). Type I interferons in host defense.
Immunity 25, 373–381.
Takeda, K., Clausen, B.E., Kaisho, T., Tsujimura, T., Terada, N., Fo¨rster, I., and
Akira, S. (1999). Enhanced Th1 activity and development of chronic enteroco-
litis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10,
39–49.Theofilopoulos, A.N., Baccala, R., Beutler, B., and Kono, D.H. (2005). Type I
interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol.
23, 307–336.
Tweezer-Zaks, N., Rabinovich, E., Lidar, M., and Livneh, A. (2008). Interferon-
alpha as a treatment modality for colchicine-resistant familial Mediterranean
fever. J. Rheumatol. 35, 1362–1365.
Van’t Wout, J.W., Van der Meer, J.W., Barza, M., and Dinarello, C.A. (1988).
Protection of neutropenic mice from lethal Candida albicans infection by
recombinant interleukin 1. Eur. J. Immunol. 18, 1143–1146.
Vonk, A.G., Netea, M.G., van Krieken, J.H., Iwakura, Y., van der Meer, J.W.,
and Kullberg, B.J. (2006). Endogenous interleukin (IL)-1 alpha and IL-1 beta
are crucial for host defense against disseminated candidiasis. J. Infect. Dis.
193, 1419–1426.
Worthington, M., and Hasenclever, H.F. (1972). Effect of an interferon
stimulator, polyinosinic: polycytidylic acid, on experimental fungus infections.
Infect. Immun. 5, 199–202.
Zang, Y.C., Skinner, S.M., Robinson, R.R., Li, S., Rivera, V.M., Hutton, G.J.,
and Zhang, J.Z. (2004). Regulation of differentiation and functional properties
of monocytes and monocyte-derived dendritic cells by interferon beta in
multiple sclerosis. Mult. Scler. 10, 499–506.Immunity 34, 213–223, February 25, 2011 ª2011 Elsevier Inc. 223
